Is less actually more when trying to liberate patients with AKI on dialysis? Read the summary 10 posts and find out
BigPAK or a bundle of balderdash?
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
LIBERATE-D: El Resumen Visual
En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE-D y, antes, no olvides revisar el resumen visual creado por Sejal Lakhani
LIBERATE-D: The Visual Abstract
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check out the VA created by Sejal Lakhani
TenPosts PISCES
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
NephJC Shorts: Hypertension and The Extreme Elderly
Fish Oil in Dialysis: A Big Catch or an Empty Net
PISCES: El Resumen Visual
¿Quieres saber cómo el uso de aceite de pescado podría reducir los eventos cardiovasculares en hemodiálisis? 🐟 Se viene una discusión imperdible por #NephJC.
No olvides revisar el resumen visual realizado por Brian Rifkin.
PISCES: The Visual Abstract
Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟
A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC!
Check out the VA made by our master Brian Rifkin
Which were the Top Nephrology Stories of 2025?
Taking the reigns
In April 2014, Swapnil and I launched NephJC—and within weeks we were overwhelmed by the sheer work of running a twice-monthly, Twitter-based journal club. Fortunately, we also had a deep bench of friends on the internet. A rotating cast of brilliant volunteers stepped in, proving the old fortune-cookie wisdom true: many hands make light work.
Over the years, both Swap and I have taken on new responsibilities and new roles. Swap even has a big announcement on the horizon. As NephJC has grown, we’ve had to confront the hardest part of any grassroots digital project: succession. The good news is we’ve been spoiled with talent. Two exceptional leaders have been (not so) quietly steering the ship for the last 18–24 months, so much so that most of you won’t notice any change at all.
Today we’re making it official:
Your new Editors-in-Chief of NephJC are Brian Rifkin and Cristina Popa.
Both are highly decorated graduates from the NSMC. Brian won Rookie of the Year in 2021 and Cristina followed right behind him in 2022. She also tacked on the MVP award in 2024.
Swap and I will still be around, but less.
Dialysis deferred, logic recycled: BICAR ICU2
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
Protein supplementation and quality of life
Do protein supplementation increase health-related QoL in advanced chronic kidney disease? Check out the recap thread made by NephJC intern Clemens Weber
Attacking the Origin of IgAN: ORIGIN3 and Atacicept
ORIGIN-3: The Visual Abstract
ORIGIN-3: El Resumen Visual
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber